Please ensure Javascript is enabled for purposes of website accessibility Global Life Sciences Fund - Janus Henderson Investors - Singapore Investor
For investors in Singapore

Global Life Sciences Fund

By understanding the science and business of health care, the strategy invests in companies addressing unmet medical needs or improving health care efficiencies

ISIN
IE00BJJMRZ35

NAV
SGD 14.21
As of 2025/05/09

1-Day Change
SGD -0.19 (-1.32%)
As of 2025/05/09

Overview

OBJECTIVE AND INVESTMENT POLICY

The Fund aims to provide capital growth over the long term.

Note: You should not make investment decisions based solely on marketing materials. You should read the Prospectus and the Product Highlights Sheet of the Fund for more details of the investment risks and seek independent professional advice where appropriate.

ABOUT THIS FUND

  • Looks to invest in companies addressing unmet medical needs or making the health care system more efficient
  • Aims to maintain a balanced portfolio across subsectors (pharmaceuticals, biotechnology, health care services, and medical devices)
  • An experienced team of specialists that seeks to understand the science and the business of health care

Portfolio Management

Andy Acker, CFA

Portfolio Manager

Industry since 1996. Joined Firm in 1999.

Daniel Lyons, Ph.D., CFA

Portfolio Manager | Research Analyst

Industry since 2000. Joined Firm in 2000.

Performance

Cumulative & Annualised Performance (%)
As of 2025/04/30
I2 HSGD (With Sales Charge)* MSCI World Health Care NR I2 HSGD (Net)
 
  Cumulative Annualised
1MO 3MO 6MO YTD 1YR 3YR 5YR 10YR Since Inception
2019/06/04
I2 HSGD (With Sales Charge)* -2.58 -7.52 -10.67 -2.26 -4.14 3.81 5.74 - 7.03
MSCI World Health Care NR -4.69 -6.63 -5.26 -1.31 -3.28 1.64 5.50 - 7.86
I2 HSGD (Net) -0.59 -5.63 -8.85 -0.26 -2.18 4.51 6.17 - 7.40

Recommended holding period 5 Years

Example Investment: SGD 10,000

Scenarios If you exit after 1 year If you exit after 5 years
MinimumThere is no minimum guaranteed return. You could lose some or all of your investment
StressWhat you might get back after costs1,390 SGD1,450 SGD
Average return each year-86.12%-32.05%
UnfavourableWhat you might get back after costs7,770 SGD10,480 SGD
Average return each year-22.34%0.94%
ModerateWhat you might get back after costs10,820 SGD15,200 SGD
Average return each year8.19%8.73%
FavourableWhat you might get back after costs13,670 SGD19,650 SGD
Average return each year36.65%14.46%
Fee Information
Initial Charge 2%
Annual Charge 1.5%
Ongoing Charge
(As of 2024/12/31)
1.57%

Portfolio

Top Holdings (As of 2025/03/31)
% of Fund
Eli Lilly & Co 9.41
UnitedHealth Group Inc 6.87
AstraZeneca PLC 4.00
Johnson & Johnson 3.59
Boston Scientific Corp 3.13
Abbott Laboratories 3.09
Sanofi SA 3.06
Amgen Inc 2.89
AbbVie Inc 2.83
Vertex Pharmaceuticals Inc 2.82
TOTAL 41.69
Sector Allocation % of Fund % of Index % of Fund % of Index As of 2025/03/31
Regional Allocation % of Fund % of Index % of Fund % of Index As of 2025/03/31

Documents